Extended Data Fig. 5: Change from baseline in lipids at Week 12 for TERN-501 monotherapy groups (Efficacy Analysis Set). | Nature Medicine

Extended Data Fig. 5: Change from baseline in lipids at Week 12 for TERN-501 monotherapy groups (Efficacy Analysis Set).

From: TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Extended Data Fig. 5

*P < 0.05; **P < 0.01 for TERN-501 monotherapy versus placebo. Error bars represent standard error. N numbers and P values are provided in Supplementary Table 3. Statistical analysis was performed using a type III sum of squares ANCOVA model with treatment group as a fixed effect and baseline value as the covariate; comparison between groups was conducted at the 2-sided, 0.05 level of significance, and no adjustments for multiplicity were made. ApoB, apolipoprotein B; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LS, least squares; TG, triglyceride.

Source data

Back to article page